Clinical studies of garenoxacin

International Journal of Antimicrobial Agents

Volumn 32, Issue 6, 2008, Pages 468-474

  Takagi, Hiroyasu ^a   Tanaka, Kiyoshi ^a   Tsuda, Hisatsugu ^a   Kobayashi, Hiroyuki ^b  

^a TOYAMA CHEMICAL CO LTD   (Japan)

^b KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

AUC MIC; Clinical efficacy; Garenoxacin; Resistance; Respiratory pathogens; Respiratory tract infections; Susceptibility

Indexed keywords

GARENOXACIN; GATIFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBIOTIC THERAPY; ANTIMICROBIAL ACTIVITY; AREA UNDER THE CURVE; ARTHROPATHY; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHMA; BACTERIAL PNEUMONIA; BLOOD PRESSURE; BRONCHIECTASIS; BRONCHIOLITIS; BRONCHITIS; CENTRAL NERVOUS SYSTEM DISEASE; CHLAMYDOPHILA PNEUMONIAE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CHRONIC RESPIRATORY TRACT DISEASE; CLINICAL TRIAL; COLITIS; DIARRHEA; DIZZINESS; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SENSITIVITY; DRUG STRUCTURE; GLUCOSE BLOOD LEVEL; HAEMOPHILUS INFLUENZAE; HEADACHE; HUMAN; INSOMNIA; LOOSE FECES; LUNG EMPHYSEMA; LUNG FIBROSIS; LUNG TUBERCULOSIS; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; MYCOPLASMA PNEUMONIA; NAUSEA; OTITIS MEDIA; PENICILLIN RESISTANCE; PHOTOALLERGY; PRIORITY JOURNAL; RASH; RHINORRHEA; SHORT SURVEY; SIDE EFFECT; SINGLE DRUG DOSE; SINUSITIS; SOMNOLENCE; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; TONSILLITIS; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; CLINICAL TRIALS, PHASE III AS TOPIC; FLUOROQUINOLONES; HUMANS; PNEUMONIA, BACTERIAL;

EID: 55249110567     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2008.06.032     Document Type: Short Survey

References (43)

1. File Jr. T.M. Streptococcus pneumoniae and community-acquired pneumonia: a cause for concern. Am J Med 117 Suppl. 3A (2004) 39S-50S
2. Jain S.K., Tunkel D.E., and Bishai W.R. Management of acute rhinosinusitis, bronchitis syndromes, and acute otitis media. Adv Stud Med 5 (2005) 344-350
3. Johnson D.M., Stilwell M.G., Fritsche T.R., and Jones R.N. Emergence of multidrug-resistant Streptococcus pneumoniae: report from the SENTRY Antimicrobial Surveillance Program (1999-2003). Diagn Microbiol Infect Dis 56 (2006) 69-74
4. Karchmer A.W. Increased antibiotic resistance in respiratory tract pathogens: PROTEKT US-an update. Clin Infect Dis 39 Suppl. 3 (2004) S142-S150
5. Croom K.F., and Goa K.L. Levofloxacin: a review of its use in the treatment of bacterial infections in the United States. Drugs 63 (2003) 2769-2802
6. Takahata M., Mitsuyama J., Yamashiro Y., Yonezawa M., Araki H., Todo Y., et al. In vitro and in vivo antimicrobial activities of T-3811ME, a novel des-F(6)-quinolone. Antimicrob Agents Chemother 43 (1999) 1077-1084
7. Fung-Tomc J.C., Minassian B., Kolek B., Huczko E., Aleksunes L., Stickle T., et al. Antibacterial spectrum of a novel des-fluoro(6) quinolone, BMS-284756. Antimicrob Agents Chemother 44 (2000) 3351-3356
8. Takahata M., Shimakura M., Hori R., Kizawa K., Todo Y., Minami S., et al. In vitro and in vivo efficacies of T-3811ME (BMS-284756) against Mycoplasma pneumoniae. Antimicrob Agents Chemother 45 (2001) 312-315
9. Hayashi K., Takahata M., Kawamura Y., and Todo Y. Synthesis, antibacterial activity, and toxicity of 7-(isoindolin-5-yl)-4-oxoquinoline-3-carboxylic acids. Discovery of the novel des-F(6)-quinolone antibacterial agent garenoxacin (T-3811 or BMS-284756). Arzneimittelforschung 52 (2002) 903-913
10. Ameyama S., Shinmura Y., and Takahata M. Inhibitory activities of quinolones against DNA gyrase of Chlamydia pneumoniae. Antimicrob Agents Chemother 47 (2003) 2327-2329
11. Stahlmann R. Clinical toxicological aspects of fluoroquinolones. Toxicol Lett 127 (2002) 269-277
12. Frothingham R. Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin. Pharmacotherapy 21 (2001) 1468-1472
13. Tamayama T., Tanaka Y., and Saito A. Analysis of patients with hypoglycemia and/or hyperglycemia induced by gatifloxacin: risk factors and patient profiles. Nippon Kagaku Ryoho Gakkai Zasshi 52 (2004) 521-529
14. Ball P. Adverse drug reactions: implications for the development of fluoroquinolones. J Antimicrob Chemother 51 Suppl. 1 (2003) 21-27
15. Nagai A., Miyazaki M., Morita T., Furubo S., Kizawa K., Fukumoto H., et al. Comparative articular toxicity of garenoxacin, a novel quinolone antimicrobial agent, in juvenile beagle dogs. J Toxicol Sci 27 (2002) 219-228
16. Nakamura T., Fukuda H., Morita Y., Soumi K., and Kawamura Y. Pharmacological evaluation of garenoxacin, a novel des-F(6)-quinolone antimicrobial agent: effects on the central nervous system. J Toxicol Sci 28 (2003) 35-45
17. Kizawa K., Fukumoto H., Sanzen T., Tsusaki H., and Todo Y. Three-month repeated oral dose toxicity study of garenoxacin in cynomolgus monkeys. Nippon Kagaku Ryoho Gakkai Zasshi 55 Suppl. 1 (2007) 42-53
18. Takahata M., Fukuda Y., Futakuchi N., Sugiura Y., Hisada H., Mizunaga S., et al. In vitro antibacterial activity of garenoxacin. Nippon Kagaku Ryoho Gakkai Zasshi 55 Suppl. 1 (2007) 1-20
19. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Sixteenth informational supplement. M100-S17. Wayne, PA, CLSI, 2007. pp. 126-8.
20. Uchida E. Phase I clinical studies of oral garenoxacin in healthy Japanese adult subjects. Nippon Kagaku Ryoho Gakkai Zasshi 55 Suppl. 1 (2007) 95-115
21. 14C]-BMS-284756 in man. In: American Association of Pharmaceutical Scientists (AAPS) Annual Meeting. 21-25 October 2001, Denver, CO, Poster #B191a.
22. Watanabe A., Niitsuma K., Takeda H., and Aoki N. Penetration into sputum study of garenoxacin in patients with secondary infection of chronic respiratory disease. Nippon Kagaku Ryoho Gakkai Zasshi 55 Suppl. 1 (2007) 162-168
23. Baba S., Suzuki K., Yamanaka N., and Yajin K. Clinical phase III open-label study of oral garenoxacin in patients with otorhinolaryngological infection. Nippon Kagaku Ryoho Gakkai Zasshi 55 Suppl. 1 (2007) 194-205
24. Baba S., Miyamoto N., Mishima T., Ando I., Ichikawa G., Yamakawa T., et al. Pharmacokinetic and clinical studies of gatifloxacin on otorhinolaryngological infections. Nippon Kagaku Ryoho Gakkai Zasshi 47 Suppl. 2 (1999) 372-386
25. Nakamura T., Tobise C., Kato H., Katai M., Hayakawa H., and Todo Y. In vitro metabolism and the effect on human cytochrome P450s of garenoxacin. Nippon Kagaku Ryoho Gakkai Zasshi 55 Suppl. 1 (2007) 87-94
26. Kobayashi H., Watanabe A., Aoki N., Odagiri S., Sano Y., and Saito A. Clinical phase II study of garenoxacin in patients with respiratory tract infections-open-label, multi-center, non-comparative. Nippon Kagaku Ryoho Gakkai Zasshi 55 Suppl. 1 (2007) 116-126
27. Lister P.D. Impact of AUC/MIC ratios on the pharmacodynamics of the des-F(6) quinolone garenoxacin (BMS-284756) is similar to other fluoroquinolones. J Antimicrob Chemother 51 (2003) 199-202
28. Nakashima M., Uematsu T., Kanamaru M., Okazaki O., and Hakusui H. Phase I study of levofloxacin, (S)-(-)-ofloxacin. Jpn J Clin Pharmacol Ther 23 (1992) 515-520
29. Ohnishi A., Toyoki T., Yoshikawa K., Hashizume K., Tanigawa T., Komori T., et al. Safety, pharmacokinetics and influence on the intestinal flora of BAY 12-8039 (moxifloxacin hydrochloride) after oral administration in healthy male subjects. Jpn Pharmacol Ther 33 (2005) 1029-1045
30. Nakashima M., Uematsu T., and Kosuge K. Phase I study of gatifloxacin, a new quinolone I. Single-dose study. Nippon Kagaku Ryoho Gakkai Zasshi 47 Suppl. 2 (1999) 175-207
31. Dalhoff A., and Schmitz F.-J. In vitro antibacterial activity and pharmacodynamics of new quinolones. Eur J Clin Microbiol Infect Dis 22 (2003) 203-221
32. Tanigawara Y, Kasai H, Nozawa K. Population pharmacokinetic analysis and Monte Carlo pharmacodynamic simulations of a new quinolone, T-3811ME (garenoxacin). In: The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 14-17 September 2003, Chicago, IL. Abstract A-6.
33. Kobayashi H., Tanigawara Y., Watanabe A., Aoki N., Sano Y., Odagiri S., et al. Phase III study of garenoxacin in patients with secondary infection of chronic respiratory disease. Nippon Kagaku Ryoho Gakkai Zasshi 55 Suppl. 1 (2007) 144-161
34. Kobayashi H., Watanabe A., Aoki N., Odagiri S., Kawai S., Niki Y., et al. Clinical phase III comparative study on garenoxacin versus levofloxacin in patients with bacterial pneumonia. Nippon Kagaku Ryoho Gakkai Zasshi 55 Suppl. 1 (2007) 127-143
35. Kohno S., Watanabe A., Aoki N., Tateda K., Taniguchi H., Niki Y., et al. Clinical phase III open-labeled study of oral garenoxacin in patients with respiratory tract infection by penicillin-resistant Streptococcus pneumoniae. Nippon Kagaku Ryoho Gakkai Zasshi 55 Suppl. 1 (2007) 185-193
36. Murakawa Y. Relationship between oral administration of garenoxacin and QT interval. Nippon Kagaku Ryoho Gakkai Zasshi 55 Suppl. 1 (2007) 214-221
37. Jacobs M.R., Felmingham D., Appelbaum P.C., Grüneberg R.N., and The Alexander Project Group. The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. J Antimicrob Chemother 52 (2003) 229-246
38. Jones R.N., and Biedenbach D.J. Comparative activity of garenoxacin (BMS 284756), a novel desfluoroquinolone, tested against 8331 isolates from community-acquired respiratory tract infections: North American results from the SENTRY Antimicrobial Surveillance Program (1999-2001). Diagn Microbiol Infect Dis 45 (2003) 273-278
39. Fuller J.D., and Low D.E. A review of Streptococcus pneumoniae infection treatment failures associated with fluoroquinolone resistance. Clin Infect Dis 41 (2005) 118-121
40. Hoban D., and Felmingham D. The PROTEKT surveillance study: antimicrobial susceptibility of Haemophilus influenzae and Moraxella catarrhalis from community-acquired respiratory tract infections. J Antimicrob Chemother 50 Suppl. S1 (2002) 49-59
41. Beekmann S.E., Heilmann K.P., Richter S.S., García-de-Lomas J., Doern G.V., and The GRASP Study Group. Antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis and group A beta-haemolytic streptococci in 2002-2003. Results of the multinational GRASP Surveillance Program. Int J Antimicrob Agents 25 (2005) 148-156
42. Saito A., Koike T., Taneichi K., Takeda T., Takeuchi K., Ohmichi M., et al. A double-blind comparative study of gatifloxacin and levofloxacin in pneumonia. Nippon Kagaku Ryoho Gakkai Zasshi 47 (1999) 712-733
43. Saito A., Ohmichi M., Ohno T., Inoue H., Sato M., Katsu M., et al. A double-blind comparative study of gatifloxacin and levofloxacin in chronic respiratory tract infections. Nippon Kagaku Ryoho Gakkai Zasshi 47 (1999) 734-757